IRIS
MUSTO, Pellegrino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.524
AS - Asia 5.540
EU - Europa 3.059
SA - Sud America 2.779
AF - Africa 271
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 2
Totale 20.180
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.292
BR - Brasile 2.378
SG - Singapore 2.273
HK - Hong Kong 1.236
VN - Vietnam 721
RU - Federazione Russa 700
CN - Cina 695
SE - Svezia 554
IT - Italia 530
DE - Germania 365
GB - Regno Unito 309
FR - Francia 187
AR - Argentina 160
BD - Bangladesh 105
IN - India 99
FI - Finlandia 98
CA - Canada 92
ID - Indonesia 86
MX - Messico 85
CI - Costa d'Avorio 77
EC - Ecuador 71
ZA - Sudafrica 60
IQ - Iraq 50
PL - Polonia 50
AT - Austria 47
TR - Turchia 47
CO - Colombia 44
PY - Paraguay 44
UA - Ucraina 38
JP - Giappone 33
IE - Irlanda 31
NL - Olanda 31
ES - Italia 28
MA - Marocco 28
UZ - Uzbekistan 24
VE - Venezuela 23
CL - Cile 22
PE - Perù 22
EG - Egitto 21
TN - Tunisia 21
CZ - Repubblica Ceca 19
PK - Pakistan 19
SA - Arabia Saudita 17
AZ - Azerbaigian 16
KE - Kenya 16
BE - Belgio 15
JO - Giordania 12
KZ - Kazakistan 12
LT - Lituania 12
DZ - Algeria 11
IL - Israele 11
DO - Repubblica Dominicana 10
HN - Honduras 10
JM - Giamaica 10
AE - Emirati Arabi Uniti 9
NP - Nepal 9
ET - Etiopia 8
OM - Oman 8
UY - Uruguay 8
SN - Senegal 7
AL - Albania 6
KR - Corea 6
LB - Libano 6
PA - Panama 6
SY - Repubblica araba siriana 6
TT - Trinidad e Tobago 6
BO - Bolivia 5
LV - Lettonia 5
BH - Bahrain 4
BY - Bielorussia 4
CR - Costa Rica 4
GE - Georgia 4
KG - Kirghizistan 4
MY - Malesia 4
PT - Portogallo 4
TW - Taiwan 4
BA - Bosnia-Erzegovina 3
CH - Svizzera 3
EE - Estonia 3
HR - Croazia 3
KH - Cambogia 3
MU - Mauritius 3
PS - Palestinian Territory 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
AO - Angola 2
BB - Barbados 2
BG - Bulgaria 2
BW - Botswana 2
CW - ???statistics.table.value.countryCode.CW??? 2
GN - Guinea 2
GY - Guiana 2
HT - Haiti 2
HU - Ungheria 2
LC - Santa Lucia 2
LK - Sri Lanka 2
NG - Nigeria 2
NO - Norvegia 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
Totale 20.150
Salva come PNG Salva come JPEG
Città #
Hong Kong 1.208
Singapore 1.189
Fairfield 1.073
Ashburn 934
New York 499
Nyköping 453
Chandler 395
Woodbridge 394
Houston 362
Lawrence 342
Seattle 338
Cambridge 337
Wilmington 294
Roxbury 284
Beijing 280
Ho Chi Minh City 276
Des Moines 236
Ann Arbor 217
São Paulo 168
Los Angeles 151
Dallas 141
Hanoi 137
San Diego 126
Paris 109
Santa Clara 96
Munich 87
London 85
Bari 79
Abidjan 77
Princeton 77
Falkenstein 67
Rio de Janeiro 59
Chicago 58
Helsinki 56
Jakarta 51
Nuremberg 51
Buffalo 50
Milan 50
Matera 48
Belo Horizonte 44
Brasília 43
Brooklyn 43
Inglewood 43
Jacksonville 43
Porto Alegre 43
Warsaw 42
Frankfurt am Main 41
Moscow 41
Boardman 40
Campinas 39
Curitiba 35
Johannesburg 35
Atlanta 34
Haiphong 33
Da Nang 31
Potenza 31
Dublin 30
Mexico City 30
Chennai 29
Guayaquil 29
Nanjing 28
Tokyo 27
Denver 26
Guangzhou 26
Ribeirão Preto 25
San Francisco 25
Shanghai 25
Montreal 24
Rome 24
Salvador 24
Dhaka 23
Tashkent 23
Orem 22
Turku 22
Hounslow 21
Vienna 21
Guarulhos 20
Kilburn 20
Phoenix 20
Salt Lake City 20
Toronto 20
Baghdad 19
Quito 19
Stockholm 19
Norwalk 18
Sorocaba 18
Boston 17
Fortaleza 17
Goiânia 17
Poplar 17
The Dalles 17
Biên Hòa 16
Buenos Aires 16
Lima 16
Piracicaba 16
Santo André 16
Baku 15
Brussels 15
Council Bluffs 15
Thái Bình 15
Totale 12.517
Salva come PNG Salva come JPEG
Nome #
Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets 177
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial 166
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 149
Amyloid in bone marrow smears of patients affected by multiple myeloma 136
Cardiovascular events and intensity of treatment in polycythemia vera. 136
90y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell trasplantation in aggressive non-Hodgkin lymphoma 131
Differences among young adults, adults, and elderly chronic myeloid leukemia patients. 130
Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM) 125
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma 122
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis 120
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 119
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis 114
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response 113
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial 110
Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice 110
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. 108
Feasibility of Optical Genome Mapping in Cytogenetic Diagnostics of Hematological Neoplasms: A New Way to Look at DNA 106
REAL-WORLD ITALIAN EXPERIENCE OF POMALIDOMIDE IN RELAPSED-REFRACTORY MYELOMA: RETROSPECTIVE MULTICENTER STUDY BY THE RETE EMATOLOGICA PUGLIESE AND BASILICATA 105
After Treatment Decrease of Bone Marrow Tregs and Outcome in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia 105
FISH analysis reveals frequent co-occurrence of 4q24/TET2 and 5q and/or 7q deletions. 104
Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells 104
RUNX1 gene alterations characterized by allelic preference in adult acute myeloid leukemia 104
Global methylation patterns in primary plasma cell leukemia 104
null 101
DARA-VD VERSUS DARA-RD AS SALVAGE THERAPY FOR PATIENTS WITH MYELOMA. INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY RETE EMATOLOGICA PUGLIESE 100
Different spatial distribution of inflammatory cells in the tumor microenvironment of ABC and GBC subgroups of diffuse large B cell lymphoma 100
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 99
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts 97
SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance 93
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma 93
Clonal Hematopoiesis at the Crossroads of Inflammatory Bowel Diseases and Hematological Malignancies: A Biological Link? 92
A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity 92
"Hemolysis, or not hemolysis, that is the question". Use of hydroxychloroquine in a patient with COVID-19 infection and G6PD deficiency 91
Nanopore sequencing approach for immunoglobulin gene analysis in chronic lymphocytic leukemia 90
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study) 89
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia 89
Epitranscriptomics in normal and malignant hematopoiesis 89
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine—Results from the Italian ‘Back to Life’ project 89
What Is New in the Treatment of Smoldering Multiple Myeloma? 86
90Y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell transplantation in aggressive non-Hodgkin lymphoma 86
null 85
SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma 84
null 82
Features, reason for testing, and changes with time of 583 paroxysmal nocturnal hemoglobinuria clones from 529 patients: a multicenter Italian study 82
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial 80
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: Updated follow-up and improved survival 80
A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias 80
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 80
Analysis of amount, size, protein phenotype and molecular content of circulating extracellular vesicles identifies new biomarkers in multiple myeloma 80
Myeloma cells regulate miRNA transfer from fibroblast-derived exosomes by expression of lncRNAs 80
Drug-related side effects after rituximab infusion in patients with chronic lymphocytic leukemia 76
Surface endoglin (CD105) expression on acute leukemia blast cells: an extensive flow cytometry study of 1002 patients 76
Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients 76
IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis 76
null 75
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: A pooled analysis of two studies 75
Exploring the Potential of Eltrombopag: Room for More? 74
A comparative analysis of biosimilar vs originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma; a propensity-score weighted multicenter approach. 73
A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia. 73
Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia 73
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 73
The Effect of the Tumor Microenvironment on Lymphoid Neoplasms Derived from B Cells 73
A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia 72
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 72
null 71
A pilot characterization of human lung NSCLC by protein pathway activation mapping 71
Cytofluorimetric and immunohistochemical comparison for detecting bone marrow infiltration in non-Hodgkin lymphomas: a study of 354 patients 71
Gastric normal adjacent mucosa versus healthy and cancer tissues: Distinctive transcriptomic profiles and biological features 70
Immunomodulatory drugs in acute myeloid leukemia treatment 70
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 70
Clonal hematopoiesis onset in chronic myeloid leukemia patients developing an adverse cardiovascular event 69
Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor 69
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma (Cancer (2008) 113, (1588-1595)) 68
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant 68
Optical Genome Mapping as a Tool to Unveil New Molecular Findings in Hematological Patients with Complex Chromosomal Rearrangements 67
IKAROS in Acute Leukemia: A Positive Influencer or a Mean Hater? 67
TNFRSF13B gene mutation in familial acute myeloid leukemia: A new piece in the complex scenario of hereditary predisposition? 67
Case report: biallelic DNMT3A mutations in acute myeloid leukemia 66
Can the new and old drugs exert an immunomodulatory effect in acute myeloid leukemia? 66
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials 66
Advanced mast cell disease: an Italian Hematological Multicenter experience 66
Inflammatory Cells in Diffuse Large B Cell Lymphoma 66
Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in Reducing the Risk of Disease Progression in Elderly or Immunocompromised Hosts Hospitalized for COVID-19: A Single Center Retrospective Study 65
Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study 65
P138 Valproic acid at therapeutic plasma levels may increase 5-azacitidine efficacy in higher risk myelodysplastic syndromes 65
CD200 and prognosis in chronic lymphocytic leukemia: Conflicting results 65
New treatment strategies for elderly myeloma patients 65
FLT3 mutational analysis in acute myeloid leukemia: Advantages and pitfalls with different approaches 65
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma 64
CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia 63
Pseudomembranous colitis in acute lymphoblastic leukaemia 62
Hypereosinophilia with a pinch of salt and pepper 62
IRF4 Gene Expression on the Trail of Molecular Response: Looking at Chronic Myeloid Leukemia from Another Perspective 62
JAK2 V617f in chronic myeloid leukemia: driving force or passive bystander? 61
Second Cancer Onset in Myeloproliferative Neoplasms: What, When, Why? 61
Meningeal Involvement in Primary Plasma Cell Leukemia 61
The Tumor Microenvironment in Classic Hodgkin’s Lymphoma in Responder and No-Responder Patients to First Line ABVD Therapy 60
Nanopore sequencing sheds a light on the FLT3 gene mutations complexity in acute promyelocytic leukemia 60
Clonal hematopoiesis in clinical practice: walking a tightrope 60
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 60
Totale 8.578
Salva come PNG Salva come JPEG
Categoria #
all - tutte 154.101
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 154.101
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.276 0 0 0 0 0 53 46 62 23 67 984 41
2021/20222.498 536 283 17 35 20 291 110 85 244 196 287 394
2022/20231.717 404 234 142 66 102 192 111 142 232 18 46 28
2023/20241.196 97 139 78 56 102 460 57 28 2 14 22 141
2024/20255.918 158 25 399 102 152 616 543 425 340 384 882 1.892
2025/20267.024 1.795 632 1.064 1.862 1.274 397 0 0 0 0 0 0
Totale 21.024